Disease consequences and regulation of autophagy-independent ATG3 activity

Ended Project Grant Awarded Last action

Award ID
F31GM149144
Recipient
Awarding agency
Obligated
$308,136

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date
Place of performance
New Haven, CT 06519, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Macroautophagy is a degradative cellular process that is upregulated in response to stress. Dysregulation of autophagy is broadly associated with several diseases including cancer, aging, and neurodegeneration. However, since this process is essential for mammalian development, diseases affecting core autophagy genes are very rare. For example, ATG3 is a core autophagy gene that is crucial for the formation of the autophagosome and there are no known disease-causing mutations within this gene. Interestingly, there is a patient with an undiagnosed severe neurodevelopmental disease found to have a point mutation in a single allele of the ATG3 gene. Intriguingly, ATG3 has been implicated in other conjugations thought to be independent of autophagy. These other conjugations regulate mitochondria and endolysosomal trafficking, both of which have significant roles in neurologic disease. My thesis work has largely focused on the patient mutation and its effect on autophagy, but my preliminary data indicates that all ATG3 activities appear to be disrupted in patient cells. Therefore, i propose to develop tools to further understand the cell biological consequences of these non-canonical ATG3 activities and use these tools to understand the effect of the patient mutation beyond autophagy. This project is designed to provide training for a successful future career in independent research. The findings from this project will improve the understanding of complex cellular processes and how they can result in disease. This proposal focuses on two aims: aim one - determine the impact of a patient mutation on lipidation- independent activities of ATG3; aim two - determine if lipidation-independent ATG3 activity is dependent on membrane binding. Aim one will use microscopy techniques i developed in patient cells and a knockout- rescue strategy in gene-edited cells to directly evaluate the impact of the mutation on the formation and downstream consequences of these autophagy-independent complexes. Aim two will capitalize on the techniques established in aim one and biochemical experiments routinely performed in our lab to investigate potential mechanisms by which these autophagy-independent ATG3 complexes are regulated and function. The work in this proposal detailing the effect of this ATG3 mutation has the potential to describe the first severe disease-producing allele of ATG3. Additionally, this work aims to distinguish and characterize previously inseparable ATG3 functions, leading to a new understanding of both foundational biological processes and their downstream clinical relevance.

Transactions

Action Obligated Date
Amendment $288
Amendment $32,769
Amendment $32,769
Amendment $48,974
Amendment $1,280
Amendment $1,280
Amendment $47,694
Amendment $47,694
Amendment $0
Amendment $0
Amendment $0
Amendment $47,694
Amendment $0
Amendment $0
Amendment $47,694
Original award $0
Show all 16

Quick answers

Who received award F31GM149144?

F31GM149144 was awarded to Yale Univ by National Institute of General Medical Sciences (National Institutes of Health) on July 1, 2024.

How much is award F31GM149144 worth?

$308,136 has been obligated on F31GM149144.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login